BCAT-IN-4 - An Overview
MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze To guage multiple intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Major demo objectives have been To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis cli